Placebo response in studies of major depression: Variable, substantial, and growing

JAMA

Volumn 287, Issue 14, 2002, Pages 1840-1847

  Timothy Walsh, B ^a,b   Seidman, Stuart N ^a,b   Sysko, Robyn ^b   Gould, Madelyn ^a,b  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; MULTICENTER STUDY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVIEW; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 0037051872     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.287.14.1840     Document Type: Review

References (112)

1. The continuing unethical use of placebo controls
2. Declaration of Helsinki should be strengthened
3. Psychiatry are placebo-controlled drug trials ethical?
4. Medicine: Placebo-controls in short-term clinical trials of hypertension
5. Placebo-controlled trials and active-control trials in the evaluation of new treatments, part 1: Ethical and scientific issues
6. When placebo controlled trials are essential and equivalence trials are inadequate
7. The use of placebo control groups in the assessment of psychiatric drugs: An historical context
8. Placebos, drug effects, and study design: A clinician's guide
9. Statistical analysis to settle ethical issues?
10. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects
11. The placebo problem remains
12. The ethics of randomized clinical trials
13. Historical controls reincarnated: An examination of techniques for clinical therapeutic research
14. Comparative clinical trials with historical controls: A statistician's view
15. Placebo controls: No news is good news
16. Improvement of phase III psychotropic drug trials by intensive phase II work
17. The failure of placebo-controlled studies: ECNP Consensus Meeting, September 13, 1997, Vienna, European College of Neuropsychopharmacology
18. Concerns about clinical drug trials
19. Consensus guidelines in the treatment of major depressive disorder
20. A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients
21. A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression
22. A comparison of fluoxetine, imipramine and placebo in patients with bipolar depressive disorder
23. A structured interview guide for the Hamilton Depression Rating Scale
24. Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression
25. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression
26. Nefazodone: Aspects of efficacy
27. Responders to antidepressant drug treatment: A study comparing nefazodone, imipramine, and placebo in patients with major depression
28. Clinical efficacy of reboxetine in major depression
29. Nomifensine, imipramine and placebo in depressed outpatients
30. A double-blind, controlled evaluation of zimeldine, imipramine and placebo in patients with primary affective disorders
31. A double-blind evaluation of zimelidine in comparison to placebo and amitriptyline in patients with major depressive disorder
32. Comparison of alprazolam, imipramine, and placebo in the treatment of depression
33. Assessing treatment response to the monoamine oxidase inhibitor isocarboxazid
34. Characteristics of responders to fluoxetine
35. Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: A controlled trial
36. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder
37. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression
38. Cianopramine and amitriptyline in the treatment of depressed patients: A placebo-controlled study
39. A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder
40. Treatment outcome validation of DSM-III depressive subtypes: Clinical usefulness in outpatients with mild to moderate depression
41. Alprazolam, amitriptyline, doxepin, and placebo in the treatment of depression
42. Imipramine and chlordiazepoxide in depressive and anxiety disorders, I: Efficacy in depressed outpatients
43. A double-blind comparative trial of zimelidine, amitriptyline, and placebo in patients with mixed anxiety and depression
44. Comparative efficacy of alprazolam, imipramine, and placebo administered once a day in treating depressed patients
45. Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression
46. Fixed-dose fluoxetine therapy for depression
47. An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology
48. Paroxetine in the treatment of depression: A comparison with imipramine and placebo
49. The predictive value of the dexamethasone suppression test: A placebo controlled study
50. Relevance of DSM-III depressive subtype and chronicity of antidepressant efficacy in atypical depression: Differential response to phenelzine, imipramine, and placebo
51. A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes
52. Double-blind, placebo- controlled, fixed dose trial of minaprine in patients with major depression
53. Clinical predictors of response to fluvoxamine, imipramine, and placebo
54. Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression
55. Clinical effects of the 5-HT1A partial agonists in depression: A composite analysis of buspirone in the treatment of depression
56. A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients
57. Antidepressant efficacy of sertraline: A double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression
58. Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorder
59. Clovoxamine in the treatment of depressed outpatients: A double-blind, parallel-group comparison against amitriptyline and placebo
60. Chronicity of depressive episode in relation to antidepressant-placebo response
61. Adinazolam, diazepam, imipramine, and placebo in major depressive disorder: A controlled study
62. A comparison of moclobemide, amitriptyline and placebo in depression: A Canadian multicentre study
63. Paroxetine versus placebo: A double-blind comparison in depressed patients
64. Moclobemide and placebo in mild major depression: A double-blind randomized trial
65. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study
66. Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression
67. Dothiepin versus doxepin in major depression: Results of a multicenter, placebo-controlled trial
68. A double-blind, placebo-controlled study comparing mianserin and amitriptyline in moderately depressed outpatients
69. A comparison of venlafaxine, trazodone, and placebo in major depression
70. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients
71. A double-blind comparison of nefazodone, imipramine, and placebo in major depression
72. Management of depression in real-life settings: Knowledge gained from large-scale clinical trials
73. Response patterns of depressed outpatients with and without melancholia: A double-blind, placebo-controlled trial of fluoxetine versus placebo
74. A multicentre comparative trial of moclobemide, imipramine and placebo in major depressive disorder
75. A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression
76. Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo
77. Moclobemide and nortriptyline in elderly depressed patients: A randomized, multicentre trial against placebo
78. A double-blind placebo-controlled study of Org 3770 in depressed outpatients
79. Treatment depressive outpatients with lorazepam, alprazolam, amytriptyline and placebo
80. A randomised, double-blind, placebo-controlled, 5-weeks' study of Org 3770 (mirtazapine) in major depression
81. Org 3770 (mirtazapine) versus trazodone: A placebo controlled trial in depressed elderly patients
82. A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients
83. Fluvoxamine maleate in the treatment of depression: A singlecenter, double-blind, placebo- controlled comparison with imipramine in outpatients
84. Zalospirone in major depression: A placebo-controlled multicenter study
85. Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses
86. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression
87. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression
88. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression
89. Buspirone and imipramine for the treatment of major depression in the elderly
90. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression
91. A Canadian multicenter study of three fixed doses of controlled-release ipsapirone in outpatients with moderate to severe major depression
92. Hypericum treatment of mild-moderate depression in a placebo-controlled study: A prospective, double-blind, randomized, placebo-controlled, multicentre study
93. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression
94. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety
95. Antidepressant action of sulpride: Results of a placebo-controlled double-blind trial
96. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline
97. A review of placebo-controlled efficacy trials for antidepressants as evaluated by the FDA
98. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the Food and Drugn Administration database
99. Use of pattern analysis to identify true drug response: A replication
100. Chronological milestones to guide drug change: When should clinicians switch antidepressants?
101. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?
102. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment
103. The different versions of the Hamilton Depression Rating Scale
104. National trends in the outpatient treatment of depression
105. Hazards of inference: The active control investigation
106. Choosing an antidepressant: Effectiveness based pharmacoeconomics
107. Evidence of early onset of antidepressant effect in randomized controlled trials
108. Measuring onset of antidepressant action in clinical trials: An overview of definitions and methodology
109. The use of placebos in randomized clinical trials of mood disorders: Well justified, but improvements in design are indicated